Your session is about to expire
← Back to Search
Ferric Carboxymaltose for Heart Failure (HEART-FID Trial)
HEART-FID Trial Summary
This trial is testing if FCM is an effective and safe treatment for heart failure with a reduced ejection fraction and iron deficiency, compared to placebo.
- Heart Failure
- Iron-Deficiency Anemia
HEART-FID Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.HEART-FID Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Why is Ferric Carboxymaltose often prescribed?
"Ferric Carboxymaltose can help address iron deficiency, problems within the oral cavity, and difficulties associated with breast feeding."
How many individuals are being researched in this clinical trial?
"This clinical trial is no longer enrolling patients. The first posting was on March 15th, 2017 and the most recent edit was on November 12th, 2021. 801 other trials are actively recruiting patients with heart failure and 22 studies are looking for participants that have been diagnosed with Ferric Carboxymaltose."
Are there any other published studies that have used Ferric Carboxymaltose?
"Ferric Carboxymaltose was first studied in 2016. Since the completion of the first trial, there have been 18,338 more. There are currently 22 active trials, a few of which are based in Alexander City, Alabama."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger